Clinical Trial

Phase I Study of OriC902 in Treatment of Advanced HCC

Name: Phase I Study of OriC902 in Treatment of Advanced HCC — clinical trial record (NCT06891742)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase I clinical study evaluating the safety, pharmacokinetics, and initial efficacy of a GPC3-targeted chimeric antigen receptor autologous T cell injection (OriC902) in GPC3-positive advanced hepatocellular carcinoma (HCC) subjects

Trial Details

NCT Number	NCT06891742
Lead Sponsor	Peking University Collaborators: OriCell Therapeutics Co., Ltd.
Conditions	HCC
Enrollment	44 participants
Start Date	2025-02-24
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-24